NewKerala.com

Key Points

Rare diseases present a significant health and societal challenge in India, affecting nearly 90 million citizens. Dr Vinod Paul from NITI Aayog emphasized that indigenous manufacturing and stronger disease registries must be prioritized. The conference highlighted progress in making five drugs available at reduced prices for seven high-burden disorders. Collaborative efforts across government, industry, and academia are essential to ensure equitable treatment and faster diagnosis for all patients.

Key Points: NITI Aayog Dr Vinod Paul Urges Indigenous Manufacturing for Rare Diseases

  • Rare diseases collectively affect an estimated 90 million people in India
  • Only a fraction of 7000 rare diseases currently have approved therapies
  • Progress made on 5 drugs for 7 diseases at drastically reduced prices
  • Multi-ministerial coordination and pooled funding models are essential for access
3 min read

Indigenous manufacturing, strong registries, multi-ministerial coordination must prioritised to treat rare diseases: NITI Aayog

Dr Vinod Paul of NITI Aayog states rare diseases affect 90 million Indians, calling for indigenous drug manufacturing, stronger registries, and multi-ministerial coordination.

"leave no one behind must serve as the guiding vision - Dr Vinod K Paul, NITI Aayog"

New Delhi, August 20

Dr Vinod K Paul, Member (Health), NITI Aayog, on Wednesday, stated that rare diseases are estimated to collectively affect close to 90 million Indians, making them both a health and societal challenge. He emphasised that with only a fraction of the 7,000 rare diseases having approved therapies, indigenous manufacturing, stronger registries, and multi-ministerial coordination must be prioritised.

Addressing the National conference on 'Rare Diseases', organised by FICCI, jointly with NITI Aayog and the Indian Medical Parliamentarians' Forum (IMPF), Dr Paul underlined that collective resolve must ensure faster diagnosis, equitable treatment, and an improved quality of life.

Reference was made to the efforts undertaken since 2023, wherein it was shared that NITI Aayog, experts, and regulators prioritised 13 high-burden disorders, with significant progress achieved in making five drugs for seven diseases available at drastically reduced prices.

He also highlighted the importance of collaboration across academia, industry, and government so that quality and affordable treatments can be developed and research can be translated into lasting cures. He further noted that the principle of "leave no one behind" must serve as the guiding vision.

Dr Anil S. Bonde, Member of Parliament and Chairperson, Indian Medical Parliamentarians' Forum, laid focus on rare diseases, though individually small, that impose a severe medical, social, and financial burden. He highlighted the responsibility of policymakers to ensure that no patient or family feels invisible and stressed the role of Parliament in keeping rare diseases firmly on the national health agenda.

Mr Amit Agrawal, Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers, Government of India, emphasised that addressing rare diseases must be seen not merely as a medical challenge but as a moral responsibility. He stated that compassion, innovation, and the courage to forge new partnerships are called for in this context.

Reference was made to government-led initiatives, which were described as catalysts for building an ecosystem that supports orphan drug development, advanced therapies, and innovative diagnostics. He further underlined that affordability must remain central, with policies being designed to encourage research while ensuring that breakthroughs are ultimately made accessible to patients in need.

Mr Amitabh Dube, Co-Chair, FICCI Pharma Committee & MD, Novartis India, opened the deliberations by stressing the extraordinary struggles patients face, emphasising access as the key challenge.

Dr Jasvantsinh Parmar, Member of Parliament & Joint Convenor, IMPF, chaired a session on Centres of Excellence and emphasised their critical role in delivering specialised care, research, and training. He urged adoption of hub-and-spoke models and greater integration of patient advocacy groups into CoE service delivery.

The conference was structured around three thematic sessions that set priorities for rare disease action. "Research, Development and Advanced Therapies," the need for expedited regulatory pathways and stronger global and domestic collaborations was emphasised. Under "Centers of Excellence: Service Delivery and Partnerships," operationalising hub-and-spoke models, establishing national protocols, and integrating patient groups were highlighted. The session on "Financing, Procurement and Access Mechanisms" proposed pooled funding from government, CSR, insurance, and philanthropy, along with outcome-based pricing and centralised procurement to enhance affordability.

It was reinforced that rare care can be realised only when therapies are made available and affordable, supported by early diagnosis, awareness, and sustainable partnerships. By convening government, parliamentarians, industry, clinicians, and patient advocates, a platform for consensus-building was established to drive coordinated action and strengthen India's rare disease ecosystem.

- ANI

Share this article:

Reader Comments

R
Rohit P
Finally some concrete action! The hub-and-spoke model for Centers of Excellence makes perfect sense for a country like India. We need to decentralize specialized care beyond metro cities.
D
David E
As someone working in pharma, I appreciate the focus on expedited regulatory pathways. India's regulatory process can be slow - this could really accelerate treatment availability for rare diseases.
A
Ananya R
The pooled funding approach from government, CSR, insurance and philanthropy is brilliant. No single entity can bear this burden alone. Collective responsibility is the way forward 💪
K
Karthik V
While the intentions are good, I hope this doesn't become another government scheme that gets lost in bureaucracy. We need strict timelines and accountability measures for these proposals.
S
Sarah B
The focus on patient advocacy groups is crucial! Patients and families living with rare diseases have invaluable insights that should guide policy and treatment development.
V
Vikram M
Early diagnosis is everything! Many rare diseases go undiagnosed for years in India due to lack of awareness. Hope this initiative includes massive awareness campaigns at grassroots level.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50